SHIKARI® (QS-NIVO) Nivolumab ELISA (mAb-Based)
NIV-SPEC-NIV
Enzyme immunoassay for the specific and quantitative determination of free Nivolumab (Opdivo®) in serum and plasma.
This kit has been especially developed for the specific and quantitative determination of free nivolumab (Opdivo®) in serum and plasma samples between the Cmin and Cmax range of concentrations.
Nivolumab is a human monoclonal antibody that specifically binds programmed death receptor-1 (PD-1). Quantification of circulating free nivolumab may be useful in pharmacokinetic, immunogenicity, and biologic drug monitoring research. This assay utilizes highly specific anti-idiotypic monoclonal antibodies to selectively detect free nivolumab molecules capable of target binding. The kit is intended for the quantitative determination of free nivolumab in biological samples for research use only.
All SHIKARI® ELISA kits are suitable for biosimilar work.
All SHIKARI® ELISA kits are produced under ISO 13485 quality system.
Research Use Only (RUO)
Research Use Only (RUO)
For technical inquiry, IFU and other relevant documents please contact techsupport@matriksbiotek.com
| Required Volume (µl) | 10 |
| Total Time (min) | 70 |
| Sample | Serum, plasma |
| Sample Number | 96 |
| Detection Limit (ng/mL) | 10 |
| Spike Recovery (%) | Between 85-115 |
| Shelf Life (month) | 6 |
| Assay type | Quantitative |
| Species Reactivity | Human |
| Storage conditions | Store at +4°C. Please refer to protocols. |
| Shipping conditions | At room temperature |
| # | File | Action |
|---|---|---|
| SDS | Download |
Publications with this drug
| # | File | Action |
|---|---|---|
| Sureda, Manuel, et al. "Therapeutic drug monitoring of nivolumab in routine clinical practice. A pilot study." Farmacia Hospitalaria 44.3 (2020): 81-86. | Visit Link | |
| Nieto, Juan C., et al. "Posttransplant cyclophosphamide after allogeneic hematopoietic cell transplantation mitigates the immune activation induced by previous nivolumab therapy." Leukemia 34.12 (2020): 3420-3425. | Visit Link | |
| Abe, Kazuki, et al. "Quantitative LC-MS/MS method for nivolumab in human serum using IgG purification and immobilized tryptic digestion." Analytical Methods 12.1 (2020): 54-62. | Visit Link | |
| Sureda, Manuel, et al. "Therapeutic drug monitoring of nivolumab in clinical practice: Preliminary experience." (2019): e14089-e14089. | Visit Link | |
| García Gil S, Ramos Díaz R., ANÁLISIS DE LA CONCENTRACIONES PLASMÁTICAS DE NIVOLUMAB EN EL TRATAMIENTO DEL CPNM | Visit Link | |
| Csató-Kovács, Erika, et al. "Development of a Mammalian Cell Line for Stable Production of Anti-PD-1." Antibodies 13.4 (2024): 82. | Visit Link | |
| Kaplan, Meryem, et al. "Codelivery of Nivolumab and Galunisertib by EGFR-Targeted Spherical Polymeric Nanoparticles for Effective Treatment of Non-small Cell Lung Cancer." Available at SSRN 6748605. | Visit Link |
